BusinesseFFECTOR Therapeutics Presents Preclinical Data for eFT508 that Demonstrates Beneficial Immunological EffectsBy Nasdaq OMXNov 10, 2017, 3:00 PM UTC
BusinessMore than 150 Colorectal Cancer Patients, Survivors, and Caregivers to Take Part in the 15th Annual National Conference focused on Patient EmpowermentBy Nasdaq OMXOct 27, 2017, 9:07 PM UTC
BusinesseFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of eFT508 and Avelumab in Microsatellite Stable Colorectal CancerBy Nasdaq OMXOct 4, 2017, 2:00 PM UTC
BusinessPatient-Friendly Clinical Trials Finder Gives Access to Clinical Trials in Real-TimeBy Nasdaq OMXJul 11, 2017, 8:04 PM UTC
BusinessColorectal Cancer Nonprofits Partner to Grow Local Grassroots AdvocacyBy Nasdaq OMXJun 29, 2017, 1:15 PM UTC
BusinessOncoMed Initiates Enrollment of Phase 1b Clinical Trial of Anti-DLL4/VEGF Bispecific Antibody as Second-line Treatment for Metastatic Colorectal Cancer PatientsBy Nasdaq OMXJan 4, 2017, 1:32 PM UTC
BusinessOncoMed Initiates Enrollment of Phase 1b Clinical Trial of Anti-DLL4/VEGF Bispecific Antibody as Second-line Treatment for Metastatic Colorectal Cancer PatientsBy Nasdaq OMXJan 4, 2017, 1:32 PM UTC
